Detection of Chemotherapy Induced Cardiotoxicity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00636844

Enrollment

Registered

2008-03-17

Start date

2008-01-31

Completion date

2012-06-30

Last updated

2013-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

chemotherapy, cardiotoxicity

Brief summary

To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).

Detailed description

To identify patients at risk of development of heart damage after receiving chemotherapy by obtaining the genetic profile of those who show: elevation of troponin, left ventricular systolic and diastolic dysfunction, and pro-oxidant stress markers.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* undergoing anthracycline and/or trastuzumab therapy for the first time

Exclusion criteria

* abnormal ventricular ejection fraction * past history of, or active cardiac disease including: MI, CHF, angina, arrhythmia requiring medication, valvular disease, uncontrolled systemic hypertension

Design outcomes

Primary

Measure	Time frame
The genetic profile of patients with anthracycline-induced elevation of troponin-I	one year

Secondary

Measure	Time frame
Assess the genetic profile of patient with anthracycline-induced left ventricular systolic and diastolic dysfunction	one year
Assess the relationship of quantitative increases of pro-oxidant stress and a specific genetic profile	one year

Countries

United States

Outcome results